建立镰状细胞贫血自动化同期队列以预测疾病修饰治疗后的生存
在美国单一转诊中心,研究利用2004年1月1日至2021年4月30日数据自动构建419例镰状细胞贫血(SCA)儿童和成人的同期队列,中位随访7.4年,47例死亡;与未接受疾病修饰治疗者相比,羟基脲治疗者死亡风险显著更低(HR=0.38;P=0.016),定期输血者无统计学差异(HR=0.71;P=0.440)。
要点
- 自动构建的SCA同期队列纳入419例持续随访患者,中位随访7.4年,死亡47例。
- 与无疾病修饰治疗相比,羟基脲治疗死亡风险显著更低(HR=0.38;P=0.016)。
- 定期输血与无疾病修饰治疗相比死亡风险无统计学差异(HR=0.71;P=0.440)。
核心结论
- 自动化同期SCA队列可用于估计儿童和成人SCA的死亡率。
研究设计与样本
- 在美国单一镰状细胞病转诊中心开展,数据获取时间为2004年1月1日至2021年4月30日。
- 纳入419例持续医疗照护的SCA患者,持续医疗照护定义为连续随访>0.5年且就诊间隔无>3.0年。
- 中位年龄10.2岁(IQR,1-24岁),中位随访7.4年(IQR,3.6-13.5年),死亡47例。
主要发现
- 98%(274/277)的儿童在18岁时仍存活,其中34.3%(94/274)随访进入成年期。
- 成人中位生存年龄为49.3岁。
- 治疗分组互斥且按层级排序:造血干细胞移植(n=22)>定期输血至少2年(n=56)>羟基脲至少1年(n=243)>无疾病修饰治疗(n=98)。
- 与无疾病修饰治疗相比,羟基脲治疗者死亡风险显著更低(HR=0.38;P=0.016)。
- 与无疾病修饰治疗相比,定期输血者死亡风险无统计学差异(HR=0.71;P=0.440)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Food and Drug Administration requires contemporaneous controls to compare clinical outcomes for participants receiving experimental gene therapy or gene editing clinical trials. However, developing a contemporaneous cohort of rare diseases requires multiple person-hours. In a single referral center for sickle cell disease, we tested the hypothesis that we could create an automated contemporaneous cohort of children and adults with sickle cell anemia (SCA) to predict mortality. Data were obtained between 1 January 2004 and 30 April 2021. We identified 419 individuals with SCA with consistent medical care defined as followed continuously for >0.5 years with no visit gaps >3.0 years. The median age was 10.2 years (IQR, 1-24 years), with a median follow-up of 7.4 years (IQR, 3.6-13.5 years) and 47 deaths. A total of 98% (274 of 277) of the children remained alive at 18 years of age, and 34.3% (94 of 274) of those children were followed into adulthood. For adults, the median age of survival was 49.3 years. Treatment groups were mutually exclusive and in a hierarchical order: hematopoietic stem cell transplant (n = 22)>regular blood transfusion for at least 2 years (n = 56)>hydroxyurea for at least 1 year (n = 243)>no disease-modifying therapy (n = 98). Compared to those receiving no disease-modifying treatment, those treated with hydroxyurea therapy had a significantly lower hazard of mortality (hazard ratio = 0.38; P = 0.016), but no statistical difference for those receiving regular blood transfusions compared to no disease-modifying therapy (hazard ratio = 0.71; P = 0.440). An automated contemporaneous SCA cohort can be generated to estimate mortality in children and adults with SCA.
引用
- Cronin RM, Wuichet K, Ghafuri DL, et al. Creating an automated contemporaneous cohort in sickle cell anemia to predict survival after disease-modifying therapy. Blood Adv. 2023. PMID: 36350716. doi:10.1182/bloodadvances.2022008692
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。